Literature DB >> 15855171

Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53.

Vita M Golubovskaya1, Richard Finch, William G Cance.   

Abstract

Focal adhesion kinase (FAK) is a nonreceptor kinase that is overexpressed in many types of tumors and associates with multiple cell surface receptors and intracellular signaling proteins through which it can play an important role in survival signaling. A link between FAK and p53 in survival signaling has been reported, although the molecular basis of these events has not been described. In the present study, we report that FAK physically and specifically interacts with p53 as demonstrated by pull-down, immunoprecipitation, and co-localization analyses. Using different constructs of N-terminal, central, and C-terminal fragments of FAK and p53 proteins, we determined that the N-terminal fragment of FAK directly interacts with the N-terminal transactivation domain of p53. Inhibition of p53 with small interfering p53 RNA resulted in a decreased complex of FAK and p53 proteins in 293 cells, and induction of p53 with doxorubicin in normal human fibroblasts caused an increase of FAK and p53 interaction. Introduction of the FAK plasmid into p53-null SAOS-2 cells was able to rescue these cells from apoptosis induced by expression of wild type p53. In HCT 116 colon cancer cells, co-transfection of FAK plasmid with p21, MDM-2, and BAX luciferase plasmids resulted in significant inhibition of p53-responsive luciferase activities, demonstrating that FAK can reduce transcriptional activity of p53. The results of the FAK and p53 interaction study strongly support the conclusion that FAK can suppress p53-mediated apoptosis and inhibit transcriptional activity of p53. This provides a novel mechanism for FAK-p53-mediated survival/apoptotic signaling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855171     DOI: 10.1074/jbc.M414172200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  77 in total

1.  Pharmacogenomic profiling and pathway analyses identify MAPK-dependent migration as an acute response to SN38 in p53 null and p53-mutant colorectal cancer cells.

Authors:  Wendy L Allen; Richard C Turkington; Leanne Stevenson; Gail Carson; Vicky M Coyle; Suzanne Hector; Philip Dunne; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Mol Cancer Ther       Date:  2012-06-04       Impact factor: 6.261

2.  A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.

Authors:  Vita M Golubovskaya; Sheila Figel; Baotran T Ho; Christopher P Johnson; Michael Yemma; Grace Huang; Min Zheng; Carl Nyberg; Andrew Magis; David A Ostrov; Irwin H Gelman; William G Cance
Journal:  Carcinogenesis       Date:  2012-03-07       Impact factor: 4.944

3.  Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated.

Authors:  Baotran Ho; Gretchen Olson; Sheila Figel; Irwin Gelman; William G Cance; Vita M Golubovskaya
Journal:  J Biol Chem       Date:  2012-04-05       Impact factor: 5.157

4.  Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.

Authors:  Ssang-Taek Lim; Xiao Lei Chen; Yangmi Lim; Dan A Hanson; Thanh-Trang Vo; Kyle Howerton; Nicholas Larocque; Susan J Fisher; David D Schlaepfer; Dusko Ilic
Journal:  Mol Cell       Date:  2008-01-18       Impact factor: 17.970

5.  TGF-beta1 modulates focal adhesion kinase expression in rat intestinal epithelial IEC-6 cells via stimulatory and inhibitory Smad binding elements.

Authors:  Mary F Walsh; Dinakar R Ampasala; Arun K Rishi; Marc D Basson
Journal:  Biochim Biophys Acta       Date:  2008-11-14

Review 6.  Focal adhesion complex proteins in epidermis and squamous cell carcinoma.

Authors:  Elizabeth K Duperret; Todd W Ridky
Journal:  Cell Cycle       Date:  2013-09-12       Impact factor: 4.534

Review 7.  Targeting the p53 pathway.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Surg Oncol Clin N Am       Date:  2013-07-30       Impact factor: 3.495

8.  Autophosphorylation-independent and -dependent functions of focal adhesion kinase during development.

Authors:  Jean-Marc Corsi; Christophe Houbron; Pierre Billuart; Isabelle Brunet; Karine Bouvrée; Anne Eichmann; Jean-Antoine Girault; Hervé Enslen
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

Review 9.  Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.

Authors:  William G Cance; Elena Kurenova; Timothy Marlowe; Vita Golubovskaya
Journal:  Sci Signal       Date:  2013-03-26       Impact factor: 8.192

10.  Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.

Authors:  Vita M Golubovskaya; Grace Huang; Baotran Ho; Michael Yemma; Carl D Morrison; Jisook Lee; Brian P Eliceiri; William G Cance
Journal:  Mol Cancer Ther       Date:  2012-12-12       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.